The EU Commission cleared the use of the drug, also
known as riociguat, for the treatment of chronic-thromboembolic
pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).
U.S. authorities approved the drug for the same uses in October.
Bayer counts Adempas among its most promising new drugs, predicting
peak annual sales of more than 500 million euros ($688 million).
($1 = 0.7271 euros)
(Reporting by Ludwig Burger; editing by Christoph Steitz)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.